The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...

Six studies in collaboration with Mayo Clinic confirm the UltraSight™ Echosystem enables non-expert clinicians to ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for high-risk U.S. patients.

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...

Doctors at a Delhi private hospital performed a minimally invasive cardiac procedure on a pre-term newborn barely 40 minutes after birth, r.

Newborn with critical heart condition undergoes successful invasive procedure in Delhi hospital | Latest News Delhi ...

PVAD IQ integrates into existing ultrasound workflows as part of UltraSight™’s Echosystem, an AI-powered software platform designed to guide healthcare professionals in performing high-quality cardiac ...

Results From The International MISSION Re-BEAT Feasibility Trial Using A Pulsatile, Soft Robotic Biventricular MCS Device That Avoids Blood Contact In Heart Failure Patients With Reduced Ejection ...

Bicuspid aortic valve affects up to one in 50 people, but many don't know they have this congenital heart defect until symptoms appear in middle age ...